TW202311248A - 經取代之雜環化合物 - Google Patents

經取代之雜環化合物 Download PDF

Info

Publication number
TW202311248A
TW202311248A TW111118147A TW111118147A TW202311248A TW 202311248 A TW202311248 A TW 202311248A TW 111118147 A TW111118147 A TW 111118147A TW 111118147 A TW111118147 A TW 111118147A TW 202311248 A TW202311248 A TW 202311248A
Authority
TW
Taiwan
Prior art keywords
compound
compounds
disease
mmol
pharmaceutically acceptable
Prior art date
Application number
TW111118147A
Other languages
English (en)
Chinese (zh)
Inventor
史帝芬 H 史伯傑爾
雷恩 M 莫斯林
麥可 艾德華 馬提斯曼
Original Assignee
美商必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商必治妥美雅史谷比公司 filed Critical 美商必治妥美雅史谷比公司
Publication of TW202311248A publication Critical patent/TW202311248A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111118147A 2021-05-14 2022-05-13 經取代之雜環化合物 TW202311248A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163188498P 2021-05-14 2021-05-14
US63/188,498 2021-05-14
US202263318508P 2022-03-10 2022-03-10
US63/318,508 2022-03-10

Publications (1)

Publication Number Publication Date
TW202311248A true TW202311248A (zh) 2023-03-16

Family

ID=81927791

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118147A TW202311248A (zh) 2021-05-14 2022-05-13 經取代之雜環化合物

Country Status (12)

Country Link
US (2) US11884650B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337648B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818623B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240008338A (cg-RX-API-DMAC7.html)
AU (1) AU2022272725A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023726A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218579A1 (cg-RX-API-DMAC7.html)
ES (1) ES3059456T3 (cg-RX-API-DMAC7.html)
IL (1) IL308422A (cg-RX-API-DMAC7.html)
MX (1) MX2023013351A (cg-RX-API-DMAC7.html)
TW (1) TW202311248A (cg-RX-API-DMAC7.html)
WO (1) WO2022241174A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI893772B (zh) * 2023-04-21 2025-08-11 大陸商浙江文達醫藥科技有限公司 作為tyk2抑制劑的雜環化合物及合成與應用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122520625A (zh) 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
EP4337650A1 (en) * 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240007242A (ko) * 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
KR102858043B1 (ko) * 2018-10-30 2025-09-10 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
US20230295119A1 (en) 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
EP4337650A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240317718A1 (en) 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240007242A (ko) 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI893772B (zh) * 2023-04-21 2025-08-11 大陸商浙江文達醫藥科技有限公司 作為tyk2抑制劑的雜環化合物及合成與應用

Also Published As

Publication number Publication date
US20240124421A1 (en) 2024-04-18
EP4337648A1 (en) 2024-03-20
US20220388987A1 (en) 2022-12-08
US11884650B2 (en) 2024-01-30
JP2024518555A (ja) 2024-05-01
JP7818623B2 (ja) 2026-02-20
CA3218579A1 (en) 2022-11-17
MX2023013351A (es) 2023-11-27
IL308422A (en) 2024-01-01
KR20240008338A (ko) 2024-01-18
WO2022241174A1 (en) 2022-11-17
BR112023023726A2 (pt) 2024-01-30
EP4337648B1 (en) 2025-12-24
AU2022272725A1 (en) 2024-01-04
ES3059456T3 (en) 2026-03-20

Similar Documents

Publication Publication Date Title
JP7490107B2 (ja) スルホンピリジンアルキルアミド置換ヘテロアリール化合物
US11884650B2 (en) Substituted heterocyclic compounds
JP6458038B2 (ja) IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物
KR102602558B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서의 포스핀 옥시드 알킬 아미드 치환된 헤테로아릴 화합물
JP7637626B2 (ja) アミド二置換のピリジンまたはピリダジン化合物
US20240270723A1 (en) Substituted heterocyclic compounds
US20250066322A1 (en) Substituted heterocyclic compounds
JP2019501125A (ja) IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物
KR20240008339A (ko) 치환된 헤테로시클릭 화합물
JP2019532092A (ja) Il−12、il−23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物
CN117321045A (zh) 经取代的杂环化合物
CN117355514A (zh) 经取代的杂环化合物
EA047032B1 (ru) Замещенные гетероциклические соединения
KR20250099236A (ko) 치환된 헤테로시클릭 화합물